Despite extensive research and hundreds of millions of infections, no government agency has yet approved an effective vaccine to prevent herpes simplex virus 2 (HSV-2) infection.
While current herpes vaccine development focuses on glycoproteins, recent studies suggest T cell responses against specific HSV-2 antigens are more prevalent in asymptomatic individuals.
Therefore, vaccine development should consider these differences in immune response to create a vaccine that can stimulate T-cell responses against these antigens.
Read More
